Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

UPMC Hillman Cancer Center

Pittsburgh, PA

UPMC Hillman Cancer Center is internationally recognized for its leadership in the prevention, detection, diagnosis, and treatment of cancer. Dedicated to excellence in clinical care, the performance of basic, translational, and clinical research, and the education of the next generation of cancer physicians and scientists, Hillman is well positioned to help reduce the global burden of cancer.

Hillman is the only NCI-designated Comprehensive Cancer Center in western Pennsylvania and among the largest integrated cancer networks in the United States, with more than 60 locations in Pennsylvania, Ohio, and western New York. Our team of more than 2,000 physicians, researchers, and staff works collaboratively to provide each patient with the latest medical, radiation, and surgical oncology treatments, access to clinical trials, and ongoing support for the physical and emotional aspects of cancer treatment. Additionally, Hillman is proud to be a part of UPMC Presbyterian Shadyside, which is currently ranked No. 7 nationally for cancer care by U.S. News and World Report.

Our investigators are leaders in cancer biology, cancer immunology and immunotherapy, cancer virology, biobehavioral cancer control, cancer epidemiology and prevention, cancer therapeutics, and genome stability. At Hillman, we are quickly advancing the latest research discoveries into pioneering therapies that can benefit the more than 113,000 patients seen each year throughout our integrated cancer care delivery network.

Website: UPMC Hillman Cancer Center

Trials at this location:

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Status: Open to Accrual
Read More

TBCRC029

Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.

Status: Closed to Accrual
Read More

TBCRC035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

Status: Closed to Accrual
Read More